Table 1.
Proposed role of rituximab in glomerular diseases
| Lupus nephritis |
| Induction of remission |
| Relapsing or refractory disease |
| Inadequate data on role as maintenance therapy |
| ANCA-associated vasculitides |
| Induction of remission |
| Combination therapy with cytoxan for induction of remission |
| Poor response in granulomatosis manifestations (orbital/pachymeningitis) |
| Inadequate data on role as maintenance therapy or timing of retreatment to prevent relapse |
| Cryoglobulinemic vasculitis |
| Hepatitis C-related |
| Non-Hepatitis C-related |
| Non-cryoglobulinemic glomerulonephritis |
| Idiopathic membranous nephropathy |
| Anti-PLA2-related diseases |
| Overcome dependency on calcineurin inhibitors |
| Autoimmune thrombotic thrombocytopenic purpura |
| Beneficial in patients with poor response to standard therapy |
| Suggestion of benefit as first-line therapy in acute TTP |
| Focal segmental glomerulosclerosis |
| Recurrent FSGS in transplanted kidney |
| Uncertain benefit in primary FSGS |